Literature DB >> 10220140

Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.

M Vihinen1, S P Kwan, T Lester, H D Ochs, I Resnick, J Väliaho, M E Conley, C I Smith.   

Abstract

X-linked agammaglobulinemia (XLA) is an immunodeficiency caused by mutations in the gene coding for Bruton agammaglobulinemia tyrosine kinase (BTK). A database (BTKbase) of BTK mutations lists 544 mutation entries from 471 unrelated families showing 341 unique molecular events. In addition to mutations, a number of variants or polymorphisms have been found. Mutations in all the five domains of BTK cause the disease, the single most common event being missense mutations. Most mutations lead to truncation of the enzyme. The mutations appear almost uniformly throughout the molecule. About one-third of point mutations affect CpG sites, which usually code for arginine residues. The putative structural implications of all the missense mutations are provided in the database. BTKbase is available at http://www.uta.fi/imt/bioinfo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220140     DOI: 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  25 in total

Review 1.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.

Authors:  Shuling Guo; Gregory Z Ferl; Rajendar Deora; Mireille Riedinger; Sheng Yin; James L Kerwin; Joseph A Loo; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-16       Impact factor: 11.205

3.  KinMutBase, a database of human disease-causing protein kinase mutations.

Authors:  K A Stenberg; P T Riikonen; M Vihinen
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

4.  X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis.

Authors:  Zaihua Zhu; Yuli Kang; Zhenlang Lin; Yanjing Huang; Huoyang Lv; Yasong Li
Journal:  Clin Rheumatol       Date:  2014-02-25       Impact factor: 2.980

5.  XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts.

Authors:  Jeroen G Noordzij; Sandra de Bruin-Versteeg; Nico G Hartwig; Corry M R Weemaes; Egbert J A Gerritsen; Eva Bernatowska; Stefaan van Lierde; Ronald de Groot; Jacques J M van Dongen
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

6.  X-linked agammaglobulinemia with hearing impairment, dystonia-parkinsonism, and progressive neurodegeneration.

Authors:  Aloysius Domingo; Thomas G P M Schmidt; Ela Barcelon; Marissa Lukban; Ana Westenberger; Christine Klein
Journal:  J Neurol       Date:  2014-10-01       Impact factor: 4.849

7.  Autoimmunity and inflammation in X-linked agammaglobulinemia.

Authors:  Vivian P Hernandez-Trujillo; Chris Scalchunes; Charlotte Cunningham-Rundles; Hans D Ochs; Francisco A Bonilla; Ken Paris; Leman Yel; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2014-06-10       Impact factor: 8.317

8.  Competing modes of self-association in the regulatory domains of Bruton's tyrosine kinase: intramolecular contact versus asymmetric homodimerization.

Authors:  Alain Laederach; Kendall W Cradic; Kristine N Brazin; Jamillah Zamoon; D Bruce Fulton; Xin-Yun Huang; Amy H Andreotti
Journal:  Protein Sci       Date:  2002-01       Impact factor: 6.725

9.  [Adult-onset primary immunodeficiencies].

Authors:  S Gadola; U Salzer; H Schultz; B Grimbacher
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

10.  Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital.

Authors:  Jin-Kyong Chun; Taek Jin Lee; Jae Woo Song; John A Linton; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.